Monopar Therapeutics (MNPR) Payables: 2016-2021
Historic Payables for Monopar Therapeutics (MNPR) over the last 6 years, with Dec 2021 value amounting to $403,967.
- Monopar Therapeutics' Payables rose 12.07% to $542,068 in Q3 2020 from the same period last year, while for Sep 2020 it was $2.2 million, marking a year-over-year increase of 15.74%. This contributed to the annual value of $403,967 for FY2021, which is 9.75% down from last year.
- Latest data reveals that Monopar Therapeutics reported Payables of $403,967 as of FY2021, which was down 9.75% from $447,598 recorded in FY2020.
- In the past 5 years, Monopar Therapeutics' Payables registered a high of $724,165 during FY2019, and its lowest value of $311,867 during FY2017.
- For the 3-year period, Monopar Therapeutics' Payables averaged around $525,243, with its median value being $447,598 (2020).
- As far as peak fluctuations go, Monopar Therapeutics' Payables spiked by 383.44% in 2017, and later plummeted by 38.19% in 2020.
- Monopar Therapeutics' Payables (Yearly) stood at $311,867 in 2017, then grew by 28.12% to $399,551 in 2018, then soared by 81.24% to $724,165 in 2019, then crashed by 38.19% to $447,598 in 2020, then declined by 9.75% to $403,967 in 2021.